Home / Market News / $MRK
benzinga Corporate Catalyst Impact 85/100 ● positive

Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16

Sep 30, 2026, 12:18 PM UTC · Primary ticker $MRK

Merck announced positive Phase 2b trial results for its investigational drug tulisokibart in treating moderate to severe hidradenitis suppurativa (HS), meeting its primary endpoint with significant improvement over placebo. This marks the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology, potentially positioning Merck for a new therapeutic market.

Merck announced that its investigational drug, tulisokibart, met its primary endpoint in a Phase 2b trial for hidradenitis suppurativa (HS), showing superior efficacy over placebo. This is significant as it represents the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology, opening a new potential market for Merck. The strong HiSCR50 rates (72% and 64% vs. 35% for placebo) and improvements in quality of life suggest a promising new treatment option for patients with moderate to severe HS, a condition with unmet medical needs. For traders, this news presents a short-term positive catalyst for MRK stock, indicating progress in its pipeline and potential for future revenue streams. The long-term implication is the potential for market entry into a new therapeutic area, strengthening Merck's pharmaceutical portfolio.

$MRK positive Successful Phase 2b trial results for a new drug candidate
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.